Clinical trials of AbbVie IL-23 inhibitors Phase 3 were positive

Psoriasis arthritis is a systemic inflammatory disease that exhibits symptoms in multiple parts of the body, including joints and skin, including joint pain, fatigue, stiffness, and red scaly rashes.
,000-year-old Risankizumab (market name Skyrizi) is an IL-23 inhibitor that specificly blocks IL-23 by binding to its p19 sub-base.
IL-23 is a cytokine involved in the inflammatory process and is thought to be associated with many chronic immuno-mediated diseases.
April 2019, Skyrizi was approved by the FDA to treat adult patients with moderate to severe plaque-like psoriasis suitable for systemic or phototherapy.
, Skyrizi is currently in Phase 3 clinical trials to treat psoriasis, Crohn's disease and psoriasis arthritis.
In both Phase 3 clinical trials, in addition to reaching the primary endpoint of the ACR20 response (indicating that the severity of the disease was reduced by at least 20% compared to the baseline), the patient's skin symptom removal rate (measured using PASI 90), physical function (using HAQ-DI index testing) and minimum disease activity (MDA) were significantly improved to reach the secondary end of the trial sequence.
"These positive results show the potential of risankizumab in psoriasis arthritis," said Dr. Michael Severino, Vice President and President of AbbVie.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
: s1. Risankizumab (SKYRIZI®) Phase 3 Results Managers in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients. Retrieved January 5, 2021, from。